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Abstract. 
 
Transforming growth factor-
 
a
 
 (TGF-
 
a
 
) is a 
member of the EGF growth factor family. Both trans-
membrane TGF-
 
a
 
 and the proteolytically released sol-
uble TGF-
 
a
 
 can bind to the EGF/TGF-
 
a
 
 tyrosine ki-
nase receptor (EGFR) and activate the EGFR-induced 
signaling pathways. We now demonstrate that trans-
membrane TGF-
 
a
 
 physically interacts with CD9, a pro-
tein with four membrane spanning domains that is fre-
quently coexpressed with TGF-
 
a
 
 in carcinomas. This 
interaction was mediated through the extracellular
domain of transmembrane TGF-
 
a
 
. CD9 expression 
strongly decreased the growth factor– and PMA-
induced proteolytic conversions of transmembrane
to soluble TGF-
 
a
 
 and strongly enhanced the TGF-
 
a
 
–induced EGFR activation, presumably in conjunc-
tion with increased expression of transmembrane
TGF-
 
a
 
. In juxtacrine assays, the CD9-induced EGFR 
hyperactivation by transmembrane TGF-
 
a
 
 resulted in 
increased proliferation. In contrast, CD9 coexpression 
with transmembrane TGF-
 
a
 
 decreased the autocrine 
growth stimulatory effect of TGF-
 
a
 
 in epithelial cells. 
This decrease was associated with increased expression 
 
of the cdk inhibitor, p21
 
CIP1
 
. These data reveal that the 
association of CD9 with transmembrane TGF-
 
a
 
 regu-
lates ligand-induced activation of the EGFR, and re-
sults in altered cell proliferation.
Key words: transforming growth factor-
 
a 
 
• CD9 • 
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Introduction
 
Transforming growth factor-
 
a
 
 (TGF-
 
a
 
)
 
1
 
 is a member of a
family of structurally related growth factors that includes
EGF, heparin-binding EGF-like growth factor (HB-EGF),
and amphiregulin (Bosenberg and Massagué, 1993). Simi-
larly to these family members, TGF-
 
a
 
 is synthesized as a
transmembrane protein that can undergo a regulated
cleavage of the ectodomain to release a soluble form of
TGF-
 
a
 
 (Bringman et al., 1987; Gentry et al., 1987). Both
the transmembrane and the soluble forms are biologically
active and able to activate the EGF receptor (EGFR), a
transmembrane tyrosine kinase (Brachmann et al., 1989;
Wong et al., 1989). The growth factor binds to the EGFR
through its 50–amino acid core sequence with a character-
istically spaced six cysteine pattern that is found in all
members of the TGF-
 
a
 
/EGF family (Derynck, 1992; Lee
et al., 1995). After ligand binding, the receptor dimer un-
dergoes autophosphorylation and, consequently, induces
signaling cascades that lead to a mitogenic response and
increased cell proliferation (Schlessinger and Ullrich,
1992). The best characterized signaling cascade, which is
induced by the activated EGFR, goes through Ras and
Raf and activates mitogen-activated protein (MAP) ki-
nases, which induce transcription of various genes (Hill
and Treisman, 1995; Treisman, 1996). In addition, EGFR
activation also induces several other signaling cascades,
such as the phosphatidylinositol-3 kinase pathway (Van-
haesebroeck et al., 1997) that activates small GTPases and
cross-talks with the MAP kinase pathway (Vojtek and
Cooper, 1995). Other members of the TGF-
 
a
 
/EGF family
also activate the EGFR or structurally closely related ty-
rosine kinase receptors (Alroy and Yarden, 1997; Riese
and Stern, 1998).
TGF-
 
a
 
 is expressed by a variety of cell types from neu-
roectodermal origin, most commonly by epithelial cells in-
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cluding keratinocytes. In these cells, the transmembrane
TGF-
 
a
 
 formed at the cell surface seems to be the predom-
inant form of TGF-
 
a
 
. In vivo, transmembrane TGF-
 
a
 
 is
likely to interact in a juxtacrine or paracrine manner with
the EGFR on neighboring cells, or in an autocrine manner
on the same cells. TGF-
 
a
 
 is also expressed in a large diver-
sity of tumors, not only in tumors of neuroectodermal ori-
gin, but also in mesenchymally derived tumors (Derynck
et al., 1987; Derynck, 1992; Lee et al., 1995). Carcinomas,
which are derived from epithelial cells, consistently ex-
press relatively high levels of TGF-
 
a
 
. Although no con-
trolled comparisons have been done, the expression of
TGF-
 
a
 
 is generally upregulated when an epithelial cell
progresses into a carcinoma cell. In addition, the pro-
teolytic cleavage of transmembrane TGF-
 
a
 
 to release sol-
uble TGF-
 
a
 
 seems to be also induced or enhanced con-
comitantly with this transition. Since carcinomas also
express EGFR, often at increased levels when compared
with normal cells (Khazaie et al., 1993), TGF-
 
a
 
 and EGFR
activation are likely to regulate tumor cell proliferation
and tumor development, a notion that is strongly sup-
ported by cell culture (Rosenthal et al., 1986; Di Marco et al.,
1989) and animal experiments (Jhappan et al., 1990; Mat-
sui et al., 1990; Sandgren et al., 1990).
In contrast to the well characterized ability of the acti-
vated EGFR to activate several signaling pathways, little is
known about how the ligands are presented to the EGFR.
Although transmembrane TGF-
 
a
 
 potently activates the
EGFR, its presentation at the cell surface and its interac-
tion with the EGFR may be regulated by accessory pro-
teins. Several putative transmembrane proteins have ge-
netically been implicated in the activation of the EGFR by
TGF-
 
a
 
–related proteins in 
 
Drosophila
 
 (Perrimon and Per-
kins, 1997), but little is known about their function at the
cellular level and about proteins that regulate the presen-
tation of TGF-
 
a
 
–related factors in vertebrates. Trans-
membrane TGF-
 
a
 
 has been shown to interact with an-
other transmembrane protein, p106, but its identity has
not been reported (Shum et al., 1994). However, trans-
membrane HB-EGF has been shown to interact with a
transmembrane protein, CD9 (Iwamoto et al., 1994), but
no interaction with transmembrane TGF-
 
a
 
 has been re-
ported.
CD9 is a 24–27-kD cell surface protein with four pre-
dicted transmembrane domains that belong to the tetraspa-
nin family. Originally identified as a surface antigen on
lymphohematopoietic cells, CD9 is expressed by epider-
mal, basophil, pre-B cells, activated T cells, platelets, as
well as neural cell lines (Maecker et al., 1997). CD9 is also
expressed in most carcinomas, the tumor types that consis-
tently express TGF-
 
a
 
 and EGFR (Miyake et al., 1996; Ca-
jot et al., 1997; Huang et al., 1998). However, little is known
about the biological function of CD9 in tumor cells or any
other cell type. CD9 has been shown to associate with sev-
eral combinations of 
 
b
 
1 integrin complexes (Hemler, 1998)
and increased CD9 expression can enhance the integrin-
dependent cell motility of B cells (Shaw et al., 1995). In ad-
dition, CD9 has also been identified as DRAP27, a protein
that enhances the affinity of the diphtheria toxin to its re-
ceptor, HB-EGF (Mitamura et al., 1992). The discovery
that HB-EGF represents the diphtheria toxin receptor was
in fact the basis for the observation that CD9 and HB-EGF
 
associate with each other (Iwamoto et al., 1994), and led to
the observation that CD9 enhances the juxtacrine mito-
genic activity of HB-EGF (S. Higashiyama et al., 1995). No
observations have linked CD9 with the biology of TGF-
 
a
 
or a potential role for CD9 in carcinoma development.
However, an inverse correlation has been found between
CD9 expression in carcinomas and the prognosis for the
behavior, invasiveness, and prognosis of the cancer (M. Hi-
gashiyama et al., 1995; Miyake et al., 1996; Cajot et al.,
1997; Huang et al., 1998).
In this report, we demonstrate that transmembrane
TGF-
 
a
 
 and CD9 interact with each other, and that this in-
teraction is mediated through the extracellular sequence
of TGF-
 
a
 
. Increased CD9 expression decreases the growth
factor–induced release of the TGF-
 
a
 
 ectodomain and en-
hances the transmembrane TGF-
 
a
 
–induced EGFR stimu-
lation. The increased EGFR activity in epithelial cells re-
sults in a high level of expression of the cdk inhibitor
p21
 
CIP1
 
, thus, decreasing the TGF-
 
a
 
–induced cell prolifer-
ation.
 
Materials and Methods
 
Plasmids
 
The mammalian expression plasmids pRK5 and pRK7 were previously
described (Graycar et al., 1989). The expression plasmid pRK7-CD9-
hygro was generated by inserting the full size CD9 coding sequence, sub-
cloned as a HindIII-XbaI fragment from pRc/CMV/CD9 (Iwamoto et al.,
1994), into pRK7-hygro. The XbaI-HindIII fragment was filled in with
Klenow DNA polymerase I and subcloned into the filled-in HindIII site of
pRK7-hygro. pRK7-hygro is a derivative of pRK7, in which the 1.7-kbp
XhoI-XbaI fragment of pREP7 (Invitrogen Corp.) that encodes the hy-
gromycin gene was inserted into the HpaI site of pRK7 by blunt end liga-
tion.
The expression plasmids for full size TGF-
 
a
 
 or the cytoplasmically
truncated version (pRK7-
 
aD
 
c) were previously described (Shum et al.,
1994). Using PCR-based approaches, the full size TGF-
 
a
 
 coding sequence
was modified to encode the derivatives TGF-
 
a
 
-myc or TGF-
 
aD
 
E. TGF-
 
a
 
-myc corresponds to the full size transmembrane TGF-
 
a
 
 with the GGE-
QKLISEEDLGG sequence, i.e., the myc epitope tag flanked by digly-
cines, inserted between amino acids 93 and 94. This location is immedi-
ately downstream the cleavage site for mature TGF-
 
a
 
 and before the
transmembrane segment. TGF-
 
aD
 
E corresponds to the transmembrane
TGF-
 
a
 
-myc from which the 50–amino acid mature TGF-
 
a
 
 was removed.
The TGF-
 
a
 
-myc and TGF-
 
aD
 
E coding sequences were inserted into the
EcoRI-HindIII sites of the pRK5 expression plasmid. pRK5-EGFR was
generated by excising the XbaI-HindIII fragment from pXER (a gift from
Dr. G. Gill, University of California, San Diego, CA) containing 3.5 kbp
of EGFR cDNA, and inserting it into the corresponding sites of pRK5.
 
Cell Culture and Transfections
 
CHO cells were cultured in Ham’s F12 medium supplemented with 10%
FBS and 10 
 
m
 
g/ml penicillin/streptomycin. 293 cells were cultured in DME
medium, supplemented with 4.5 g glucose per liter, 10% FBS, and 10 
 
m
 
g/ml
penicillin/streptomycin. MDCK cells were grown in DME medium, sup-
plemented with 4.5 g glucose per liter, 10% FBS, and 10 
 
m
 
g/ml penicillin/
streptomycin. WEHI-3B cells were cultured in RPMI 1640 medium sup-
plemented with 15% FBS, 10 
 
m
 
g penicillin/streptomycin. 32D cells and
32D-EGFR (EP170.7) cells (Pierce et al., 1988) were grown in suspension
in RPMI 1640 medium with 10% FBS, 5% WEHI-3B conditioned me-
dium. Stable transfected MDCK cell lines were maintained in the pres-
ence of 400 
 
m
 
g/ml G418 (for neomycin resistance) or 200 
 
m
 
g/ml hygromy-
cin (for hygromycin resistance).
Stable transfected MDCK cells expressing TGF-
 
a
 
 were obtained from
Dr. R. Coffey (Vanderbilt University Medical School, Nashville, TN)
(Dempsey and Coffey, 1994). These cells and the parental MDCK cells
were transfected with pRK7-CD9-hygro using the calcium phosphate pre-
cipitation method (Ausubel et al., 1997). Transfected single colonies were 
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selected in the presence of 400 
 
m
 
g/ml hygromycin, isolated 12 d after
transfection, and screened for CD9 expression by immunofluorescence.
 
Metabolic Labeling, Coimmunoprecipitation, and 
Immunoblot Analysis
 
Metabolic labeling and coimmunoprecipitations were carried out essen-
tially as described (Shum et al., 1994). In brief, the supernatants of the lysed
293, CHO, or MDCK cells were precleared with protein A–Sepharose
(Pharmacia), and conjugated with rabbit anti–mouse IgG (Jackson Immu-
noResearch Labs), for 1 h at 4
 
8
 
C. After centrifugation, the precleared su-
pernatants were incubated at 4
 
8
 
C for 2 h with the anti–TGF-
 
a
 
 mAb 
 
a
 
1 (5
 
m
 
g/ml) (Bringman et al., 1987) or the anti–EGFR antibody Ab-5 (Calbio-
chem-Novabiochem) and protein A–Sepharose preloaded with rabbit
anti–mouse IgG. The immunoprecipitated samples were washed three
times with lysis buffer, incubated in SDS-Laemmli sample (Laemmli,
1970), and analyzed by SDS-PAGE. For cell surface immunoprecipitation
of transmembrane TGF-
 
a
 
, cells were first incubated with the 
 
a
 
1 mAb
(Bringman et al., 1987) for 2 h at 4
 
8
 
C, and then washed and lysed in Triton
lysis buffer. The lysate was subjected to immunoprecipitation as described
above.
For Western blotting, the immunoprecipitated protein membranes sep-
arated by SDS-PAGE, were electrotransferred onto nitrocellulose using a
Mini Transblot Apparatus (Bio-Rad Laboratories). The immunoblots
were pretreated with 5% BSA (for antiphosphotyrosine Western blots) or
5% dry milk (for the use of other antibodies) in TBST (20 mM Tris-HCl,
pH 7.5, 137 mM NaCl, and 0.1% Tween) for 1 h at room temperature. Af-
ter three washes with TBST, antibody was added at a concentration of
1–10 
 
m
 
g/ml in TBST, and the incubation proceeded overnight at 4
 
8
 
C. The
blot was washed again three times and incubated with a 1:2,500-fold di-
luted HRP-conjugated goat anti–mouse IgG (Amersham Inc.) for 1 h at
room temperature. The blots were washed again and developed using
ECL substrates (Pierce Chemical Co.). Anti–TGF-
 
a
 
 antibody was pur-
chased from Calbiochem-Novabiochem, anti–CD9 and anti–p21 antibod-
ies from PharMingen, and antiphosphotyrosine antibody from Transduc-
tion Laboratories.
 
Measurement of Transmembrane TGF-
 
a
 
 Cleavage
 
The release of soluble TGF-
 
a
 
 from transmembrane TGF-
 
a
 
 was measured
in transiently transfected CHO cells, as described previously (Fan and
Derynck, 1999). In brief, CHO cells, grown in 6-well plates, were trans-
fected using Lipofectamine (GIBCO BRL) with 0.2 
 
m
 
g pRK7-TGF-
 
a
 
 with
or without 1 
 
m
 
g pRK7-CD9-hygro or the control plasmid pRK7-hygro.
Cells were switched into F12 medium, supplemented with 10% FBS, cul-
tured for another 5 h, and then serum-starved overnight. To analyze the
levels of cell-associated TGF-
 
a
 
, cells were pulse-labeled with [
 
35
 
S]me-
thionine/cysteine in F12 medium for 20 min, rinsed with medium, and in-
cubated for 1 h at 37
 
8
 
C in F12/DME (1:1) medium, 0.1% BSA with or
without 10% heat-inactivated FBS, or 10 nM PMA. Cells were again
rinsed with cold medium and lysed in TBS containing 1% NP-40. Trans-
membrane TGF-
 
a
 
 was immunoprecipitated from the cell extracts using
the mAb 
 
a
 
1 (Bringman et al., 1987), the immunoprecipitates were ana-
lyzed by SDS-PAGE and autoradiography, and levels of transmembrane
TGF-
 
a
 
 were quantitated by ImageQuant software (Molecular Dynamics).
To measure the levels of soluble TGF-
 
a
 
 in the medium, [
 
35
 
S]methionine/
cysteine labeling was performed for 2 h. Soluble TGF-
 
a
 
, which was re-
leased into the medium, was analyzed by immunoprecipitation followed
by gel analysis or liquid scintillation counting.
 
Immunofluorescence
 
Cells were grown in 4-well chamber slides (Falcon Plastics) and fixed with
3.7% formaldehyde in PBS for 
 
z
 
10 min. They were rinsed twice with PBS
and permeabilized with 0.1% Triton-X 100, 1% BSA in PBS for 7 min,
washed twice with PBS with a 5-min interval, and treated with 3% BSA in
PBS for 30 min. After washing with PBS, the cells were incubated with the
 
a
 
1 mAb (4 
 
m
 
g/ml) in 2% horse serum in PBS for 1 h at room temperature.
The unbound antibody was removed by repeated washes in PBS. The cells
were incubated with rhodamine (TRITC)-conjugated affinity-purified
donkey anti–mouse IgG (H 
 
1 
 
L) (Jackson ImmunoResearch Laborato-
ries, Inc.) (4 
 
m
 
g/ml) for 30–60 min. After washing the cells thoroughly with
PBS, the slides were mounted with Gel-mount (Sigma Chemical Co.). All
procedures were performed at room temperature. The fluorescence stain-
ing was examined with a Nikon fluorescence microscope.
 
Measurements of DNA Synthesis
 
Cells were plated at 2 
 
3
 
 10
 
4
 
 cells/well in 12-well plates in normal culture
medium and incubated overnight. 300 
 
m
 
l of serum-free medium contain-
ing 4 
 
m
 
Ci/ml of [
 
3
 
H]thymidine was added and incubation proceeded for 4 h
at 37
 
8
 
C. After removal of the medium, the cells were washed twice with
ice-cold 5% TCA and three times with ice-cold water. The cells were lysed
with 250 
 
m
 
l 0.5 M NaOH, and the incorporated [
 
3
 
H]thymidine in the cell
lysates was determined using liquid scintillation counting.
 
Determination of Cell Numbers
MDCK cells were plated at 40% confluency in multiple 60-mm diam
plates. At daily intervals after plating, one plate of cells was trypsinized
and the cells were resuspended in 5 ml medium. The cells in a 10-ml sam-
ple were counted, and the total cell number was calculated as a function of
time to determine the growth rate.
Measurement of Juxtacrine Growth Stimulation
CHO cells, which either express transmembrane TGF-a or not, were
tested for their ability to stimulate proliferation of 32D-EGFR cells
through cell–cell contact. The method was modified from S. Higashiyama et
al. (1995). CHO cells were plated to 50% confluence in 12-well plates and
incubated for 12 h at 378C. The cells, either live or formalin-fixed, were
washed with RPMI 1640 medium containing 10% FBS. 1 3 105 32D or
32D-EGFR cells were added in the same medium. After 24 h, [3H]thymi-
dine (1 mCi/well/500 ml) was added, and incubation proceeded for 4 h at
378C. Subsequently, the 32D or 32D-EGFR cells were gently removed,
collected on a nitrocellulose filter, and [3H]thymidine incorporation was
measured using liquid scintillation counting.
Results
Physical Interaction of CD9 with
Transmembrane TGF-a
It has been reported that CD9 interacts with pro-HB-
EGF, but not transmembrane TGF-a. Since transmem-
brane TGF-a and pro-HB-EGF both have a structurally
related extracellular domain sequence with six conserved
cysteines, we evaluated whether CD9 physically associates
with transmembrane TGF-a. As shown in Fig. 1, A and B,
CD9 coimmunoprecipitated with transmembrane TGF-a.
No interaction was seen with another transmembrane pro-
tein, such as the type II TGF-b receptor (data not shown).
In addition, CD9 did not interact with the EGFR, the re-
ceptor for TGF-a (Fig. 1 C).
To characterize the structural basis of this interaction,
we evaluated the ability of CD9 to associate with several
derivatives of transmembrane TGF-a. One of these, TGF-
aDC, lacked the cytoplasmic domain but still associated
with CD9, indicating that the cytoplasmic domain of trans-
membrane TGF-a is not required for this interaction (Fig.
2 A). To assess whether the extracellular domain of trans-
membrane TGF-a plays a role in the association with
CD9, we also examined the interaction with a derivative of
the transmembrane TGF-a, TGF-aDE. In TGF-aDE, the
50–amino acid core sequence of fully processed TGF-a
was replaced with a Myc epitope tag. CD9 was unable to
associate with this derivative of transmembrane TGF-a
(Fig. 2 A), suggesting that the 50–amino acid core TGF-a
sequence is required for this interaction. In control experi-
ments, CD9 still coprecipitated with a derivative of trans-
membrane TGF-a in which the 50–amino acid TGF-a core
was followed by the Myc epitope sequence (data not
shown), strongly suggesting that the Myc antibody doesThe Journal of Cell Biology, Volume 148, 2000 594
not interfere with the association with CD9. Finally, ex-
pression of HB-EGF decreased the level of CD9 that asso-
ciated with transmembrane TGF-a (Fig. 2 B), strongly
suggesting that transmembrane HB-EGF and TGF-a
compete with each other for interaction with CD9. This
observation further supports the notion that the 50–amino
acid core TGF-a sequence is essential for association with
CD9, since the sequence similarity of transmembrane HB-
EGF and TGF-a is only apparent in this core segment.
CD9 Coexpression Inhibits Growth Factor– and
PMA-induced Transmembrane TGF-a Cleavage
The interaction of CD9 with the extracellular domain of
transmembrane TGF-a raises the possibility that CD9
association regulates the cleavage of the ectodomain
of transmembrane TGF-a. This cleavage occurs immedi-
ately downstream from the 50–amino acid core sequence
through the action of a cell surface–associated metallopro-
tease (Arribas et al., 1996), and results in the release of the
soluble growth factor. In cell culture, TGF-a–expressing
cells undergo a basal level of soluble TGF-a release, which
is controlled by the p38 MAP kinase signaling cascade,
whereas growth factor receptor–stimulated TGF-a ecto-
domain release (e.g., in response to EGFR activation) is
mediated through the Erk/MAP kinase pathway (Fan and
Derynck, 1999). Therefore, we evaluated the ability of se-
rum, a source of growth factors such as PDGF, to induce
ectodomain cleavage and consequent release of soluble
TGF-a. As shown in Fig. 3, the serum- and PMA-induced
release of soluble TGF-a, as assessed by the levels of both
the soluble TGF-a in the medium and the cell surface–
associated transmembrane TGF-a, were strongly inhibited
by CD9. These results suggest that the interaction of CD9
with transmembrane TGF-a strongly decreases its suscep-
tibility to ectodomain cleavage.
Increased EGFR Activation in Cells Coexpressing 
Transmembrane TGF-a and CD9
To assess the physiological effects of CD9 on the activity
of transmembrane TGF-a, we expressed CD9, TGF-a, or
both in CHO cells, which lack endogenous EGFR, and in
MDCK cells, which express EGFR endogenously. Stably
transfected CHO cells were tested for their ability to stim-
ulate EGF receptors on transfected 32D cells, a hemato-
poietic cell line that lacks endogenous EGFR and the re-
lated HER-2, -3, and - 4 receptors, but was transfected to
express EGFR (Pierce et al., 1988). Direct cell contact be-
tween CHO cells expressing transmembrane TGF-a and
Figure 1. Association of CD9
with transmembrane TGF-a.
(A) Anti–TGF-a immuno-
precipitates of 35S-labeled,
transfected 293 cell lysates
were analyzed using SDS-
PAGE. Cells were trans-
fected with control pRK5
plasmid (lane 1), pRK7-
TGF-a (lane 2), pRK7-CD9
(lane 3), and pRK7-TGF-a
and pRK7-CD9 (lane 4).
The previously characterized
three transmembrane forms
of TGF-a (Bringman et al.,
1987) are marked. CD9 is
marked with an arrow. As
shown, CD9 coprecipitates
with transmembrane TGF-a.
(B) Anti–TGF-a immuno-
precipitates of unlabeled,
transfected 293 cells were an-
alyzed by Western blotting
using an anti–CD9 antibody.
Cells were transfected with
control pRK5 plasmid (lane
1) or with expression plas-
mids for TGF-a and/or CD9,
as marked (lanes 2–4). CD9
is marked with an arrow,
whereas nonspecific bands
are not marked. (C) CD9
does not associate with the
EGFR. Anti–TGF-a or anti-
EGFR immunoprecipitates
of unlabeled, transfected
CHO cells were analyzed by
Western blotting using an
anti–CD9 antibody. Cells were transfected with expression plas-
mids for TGF-a and/or CD9, as marked. CD9 is marked with an
arrow, whereas nonspecific bands are not marked.
Figure 2. CD9 interacts with
the extracellular domain of
transmembrane TGF-a. (A)
Interaction of CD9 with de-
letion mutants of trans-
membrane TGF-a. Anti–
TGF-a immunoprecipitates
of 35S-labeled, transfected
293 cell lysates were analyzed
using SDS-PAGE. Cells were
transfected with expression
plasmids for transmembrane
TGF-a (a), a cytoplasmically
truncated transmembrane
TGF-a ( aDC) or a trans-
membrane TGF-a mutant
lacking the extracellular TGF-a
core sequence (aDE), with or
without an expression plas-
mid for CD9. The arrow-
heads show CD9, which co-
precipitates with transmembrane forms of wild-type TGF-a or
TGF-aDC but not with TGF-aDE. The bullets show the three
transmembrane TGF-a forms, which in the case of aDC and aDE
are predictably smaller in size than in wild-type TGF-a. (B) Co-
expression of HB-EGF competes with binding of transmembrane
TGF-a to CD9. CHO cells were transfected with expression plas-
mids for TGF-a with or without CD9, in the presence or absence
of transmembrane HB-EGF coexpression. Immunoprecipitation
of transmembrane TGF-a resulted in coprecipitation of CD9, as
shown in lane 3, and the level of coprecipitated CD9 was consid-
erably less, when HB-EGF was coexpressed (lane 4). In this ex-
periment, the expression of the three transmembrane TGF-a
forms (marked with bullets) is considerably less than in Fig. 1 A.Shi et al. CD9 Interacts with Transmembrane TGF-a 595
32D-EGFR cells allowed transmembrane TGF-a to stimu-
late the tyrosine autophosphorylation of the EGFR, a
measure of juxtacrine receptor activation induced by
TGF-a. In contrast, cells expressing only CD9 did not
stimulate EGFR autophosphorylation. Coexpression of
CD9 with transmembrane TGF-a, however, resulted in a
higher level of EGFR receptor activation than TGF-a
alone (Fig. 4 A). This was observed using both live CHO
cells (Fig. 4 A) or fixed CHO cells, which do not have the
ability to release soluble TGF-a (data not shown), as do-
nor cells.
We also generated stably transfected MDCK cells,
which express TGF-a, CD9, or both. Like most epithelial
cells, MDCK cells make low levels of endogenous TGF-a
and EGFR, and the autocrine stimulation of the EGFR by
TGF-a is thought to be important for epithelial cell prolif-
eration (Tsao et al., 1996). The expression levels of TGF-a
and CD9 were considerably lower than in the transfected
CHO cells (data not shown). Using these stable cell lines,
we evaluated the level of EGFR tyrosine phosphorylation
as a measure of autocrine, TGF-a–induced receptor acti-
vation. The MDCK cells that coexpressed TGF-a and
CD9 showed a higher level of EGFR activation than the
cells expressing only TGF-a (Fig. 4 B). This result is con-
sistent with the higher level of juxtacrine EGFR stimula-
tion of 32D cells by TGF-a/CD9 coexpressing CHO cells,
when compared with TGF-a–expressing cells (Fig. 4 A).
The low level of EGFR phosphorylation in the control-
transfected MDCK cells or the MDCK cells expressing
CD9 alone is most likely due to stimulation by endoge-
nous TGF-a.
We next evaluated whether the increased EGFR stimu-
lation was due to an increased ability of transmembrane
TGF-a to activate the receptor and/or an increased num-
ber of transmembrane TGF-a proteins at the cell surface.
As shown in Fig. 5 A, coexpression of CD9 resulted in in-
creased expression of transmembrane TGF-a both at the
cell surface of stably transfected CHO cells (Fig. 5 A) and
in total cell lysates of the MDCK cells (data not shown).
This increased expression of transmembrane TGF-a, when
CD9 was coexpressed, was consistently seen in multiple
stably transfected CHO (data not shown) and MDCK cell
clones (Fig. 5 B). Immunofluorescence staining of perme-
abilized MDCK cells also demonstrated increased trans-
Figure 3. CD9 expression inhib-
its the serum- or PMA-induced
proteolytic release of soluble
TGF-a. (A) CD9 expression de-
creases the serum- or PMA-
induced release of soluble
TGF-a into the medium. The
bottom panel shows the soluble
TGF-a in the medium; the
smaller form is the 50–amino
acid form, whereas the larger
one, which is much lighter in in-
tensity, is the glycosylated form.
The top panel shows the average
values of duplicate samples,
based on liquid scintillation
counting of the immunoprecipi-
tated TGF-a in the medium. The
amounts of free TGF-a released
into the medium were normalized to the 100% value for the unstimulated control samples (B) The serum- or PMA-induced processing
of transmembrane TGF-a is decreased in the presence of CD9. Transmembrane TGF-a was immunoprecipitated from the lysates and
visualized by SDS-PAGE and autoradiography (bottom). As shown, serum or PMA induced ectodomain cleavage and a resulting de-
crease of transmembrane TGF-a. CD9 inhibited this decrease in cell-associated TGF-a. The top panel shows a quantitation of the cell-
associated TGF-a by phosphoimage analysis of the immunoprecipitated cell-associated TGF-a. All experiments were carried out in du-
plicate, and the values were averaged and normalized to the 100% value for the unstimulated control samples.
Figure 4. Increased EGFR tyrosine phosphorylation in response
to transmembrane TGF-a/CD9 costimulation. (A) 32D cells or
EGFR expressing 32D cells (32D-EGFR) were brought in con-
tact with CHO cells expressing transmembrane TGF-a, CD9, or
both, as shown. EGFR tyrosine phosphorylation in the 32D-
EGFR cells was assessed by antiphosphotyrosine Western blot-
ting reactivity of the 170-kD EGFR band using equal amounts of
cell lysate protein. The autoradiographic intensity of the phos-
phorylated EGFR, induced by TGF-a/CD9 coexpressing cells (a/
CD9), was 1.33-fold higher than the EGFR phosphorylation, in-
duced by TGF-a–expressing cells (a), as assessed by scanning of
the autoradiogram. (B) Tyrosine phosphorylation of endogenous
EGFR in MDCK cells, stably transfected with expression plas-
mids for transmembrane TGF-a, CD9, or both. EGFR tyrosine
phosphorylation was assessed as in A. Scanning revealed a 1.42-
fold higher intensity of the phosphorylated EGFR band in TGF-
a/CD9 coexpressing cells (a/CD9), when compared with the cells
that only overexpress TGF-a (a).The Journal of Cell Biology, Volume 148, 2000 596
membrane TGF-a not only at the cell surface, but also in
the perinuclear region (Fig. 5 C). The increase in juxta-
crine and autocrine EGFR activation in 32D and MDCK
cells, respectively, is therefore not necessarily a direct con-
sequence of the interaction of CD9 with transmembrane
TGF-a per se, but may result from the increased trans-
membrane TGF-a levels at the surface of cells that coex-
press CD9.
Coexpression of CD9 Enhances the Juxtacrine, but 
Decreases the Autocrine Mitogenic Activity of 
Transmembrane TGF-a
We next assessed the effect of CD9 expression on the abil-
ity of transmembrane TGF-a to stimulate the EGFR-
induced DNA synthesis and cell proliferation. Coculture
of cells expressing transmembrane TGF-a with EGFR-
expressing 32D cells allowed us to measure the juxtacrine
activity of transmembrane TGF-a. CHO cells, which lack
endogenous TGF-a and EGFR did not induce [3H]dT
incorporation in the 32D-EGFR cells, nor did TGF-
a–expressing CHO cells stimulate the DNA synthesis in
Figure 5. CD9 coexpression enhances the cell surface presenta-
tion of transmembrane TGF-a. (A) Cell surface expression of
transmembrane TGF-a in CHO cells, stably transfected with ex-
pression plasmids for TGF-a, CD9, or both. Intact cells were in-
cubated with the anti–TGF-a mAb a1, before lysis and anti–
TGF-a immunoprecipitation, followed by anti–TGF-a Western
blotting using Ab-1 antibody (Calbiochem-Novabiochem). The
three forms of transmembrane TGF-a are marked. The nature of
the sharp, unmarked band is not known, but may be due to an ar-
tifact in gel migration. Scanning of the upper and lower TGF-a
band on the autoradiogram revealed a 1.68- and 1.24-fold higher
intensity, respectively, in the TGF-a/CD9 coexpressing cells (a/
CD9) when compared with the cells that only overexpress TGF-a
(a). (B) CD9 coexpression results in enhanced levels of trans-
membrane TGF-a in MDCK clones. Besides the clone, marked
a/CD9, which was used in further experiments, another clone
(clone 2) also showed enhanced TGF-a levels when compared
with the TGF-a overexpressing MDCK cells (marked a). Control
marks the parental MDCK cells, which did not overexpress
TGF-a or CD9, whereas CD9 designates MDCK cells that over-
express CD9 but not TGF-a. Transmembrane TGF-a was as-
sessed by immunoprecipitation with anti–TGF-a antibody, fol-
lowed by Western blot using anti–TGF-a antibody. The TGF-a
form shown corresponds to the large glycosylated form. The non-
specific band was detectable in all lanes. (C) Immunostaining of
transmembrane TGF-a in permeabilized MDCK cells, stably
transfected with an expression plasmid for TGF-a in the absence
(left) or presence (right) of overexpressed CD9. Immunoprecipi-
tation of 35S-labeled cell lysates confirmed the higher expression
of transmembrane TGF-a in TGF-a/CD9 coexpressing cells,
which, based on scanning of the autoradiogram, was 4.4-fold
higher than in the cells that only overexpress TGF-a (data not
shown).
Figure 6. CD9 increases the juxtacrine transmembrane TGF-
a–induced DNA synthesis. (A) 32D cells, either parental or
EGFR-expressing cells, were laid on top of a confluent mono-
layer of live CHO cells expressing TGF-a, CD9, or both (as
marked), and [3H]dT incorporation in the 32D cells was mea-
sured. The values, shown as bar graphs, represent the averages of
triplicates in two independent experiments with their SEM. (B)
Cell number–dependent, juxtacrine stimulation of DNA synthe-
sis. The experiments were done as in A, except that the 32D cells
were incubated with different numbers of fixed CHO cells, as
shown in the abscissa. Only the EGFR expressing 32D cells were
stimulated by TGF-a–expressing CHO cells, and this stimulation
was higher when TGF-a was coexpressed with CD9. None of the
other cell combinations showed stimulation. In several cases, the
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parental 32D cells, which lack EGFR expression. In addi-
tion, expression of CD9 alone did not affect the DNA syn-
thesis in EGFR-expressing 32D cells either. In contrast,
TGF-a–expressing CHO cells stimulated DNA synthesis
in EGFR-expressing 32D cells, and this stimulation was
substantially increased when CD9 was coexpressed with
transmembrane TGF-a. This was demonstrated using both
live (Fig. 6 A) or fixed donor CHO cells (Fig. 6 B). The ba-
sis for the higher level of DNA synthesis in control- or
CD9-stimulated 32D-EGFR cells, when compared with
the parental 32D cells (Fig. 6 A), is unclear but may be re-
lated to a background activity of the EGFR in the absence
of exogenous stimulation.
Consistent with the ability of transmembrane TGF-a to
activate the EGFR in 32D cells, the TGF-a–expressing
MDCK cells had a higher rate of DNA synthesis and cell
proliferation than control-transfected MDCK cells (Fig. 7,
A and B). This observation is also consistent with the
growth stimulatory activity of soluble TGF-a on these
cells (data not shown) and many other cell lines. The rate
of DNA synthesis and cell proliferation of CD9-expressing
cells was comparable to the control cells. In contrast to the
TGF-a–expressing MDCK cells, coexpression of CD9 and
transmembrane TGF-a resulted in a lower rate of DNA
synthesis (Fig. 7 A) and cell proliferation (Fig. 7 B). This
effect of CD9 was remarkable since the expression level of
transmembrane TGF-a and the level of EGFR activation
were considerably higher in these cells than in the TGF-
a–expressing MDCK cells. Such a growth inhibitory activ-
ity could not be mimicked by addition of high levels of sol-
uble TGF-a to these cells (data not shown). This result is
also in contrast with the ability of coexpressed CD9 to en-
hance the juxtacrine, TGF-a–induced stimulation of DNA
synthesis in 32D cells (Fig. 6 A). Furthermore, the expres-
sion level of transmembrane TGF-a in the CHO cells that
were used in the juxtacrine stimulation assays, was consid-
erably higher than in MDCK cells used in the autocrine
stimulation (data not shown).
These results indicate that CD9 coexpression with trans-
membrane TGF-a results in increased transmembrane
TGF-a levels at the cell surface and increased activation of
the EGFR both in a juxtacrine (32D cells) and autocrine
(MDCK cells) manner. Cells expressing both CD9 and
TGF-a induced an enhanced juxtacrine stimulation of
DNA synthesis and proliferation of 32D-EGFR cells.
However, the strong increase in EGFR activation in
MDCK cells, expressing both CD9 and TGF-a, resulted in
growth inhibition, when compared with MDCK cells ex-
pressing only transmembrane TGF-a.
The CD9-induced Growth Inhibition in 
Transmembrane TGF-a–Expressing Cells Correlates 
with Increased p21CIP1 Expression
Although moderate activation of Raf, an effector of Ras
signaling and stimulator of MAP kinase activation, results
in stimulation of cell proliferation, a high level activation
of Raf (Sewing et al., 1997; Woods et al., 1997) or Ras (Pu-
miglia and Decker, 1997; Olson et al., 1998) has been
shown to stimulate the expression of the cdk inhibitor,
p21CIP1. When stimulated beyond a certain threshold level,
p21CIP1 is able to induce growth arrest. Since Ras, Raf and
MAP kinase signaling are activated in response to EGF
receptor activation (Schlessinger and Ullrich, 1992), we
examined whether an increase in p21CIP1 expression could
be the basis of the growth inhibition of the MDCK cells,
which coexpress CD9 and transmembrane TGF-a.
As shown in Fig. 7 C, the level of p21CIP1 expression was
considerably higher in MDCK cells, which coexpress
transmembrane TGF-a and CD9, when compared with
parental MDCK cells or the TGF-a–expressing MDCK
cells. Cells expressing TGF-a alone also had enhanced
p21CIP1 expression, albeit to a considerably lower level
than in cells coexpressing CD9 and TGF-a. Thus, the level
of p21CIP1 expression correlated with the level of EGFR
activation (Fig. 4 B). Furthermore, the high level of
p21CIP1 and its role as an inducer of growth arrest also cor-
related with the lower level of proliferation of the TGF-a/
CD9 coexpressing cells, when compared with cells ex-
pressing TGF-a alone. The levels of p21CIP1 in these
MDCK cell lines correlated with the transcription levels
Figure 7. CD9 decreases the autocrine transmembrane TGF-
a–induced DNA synthesis. (A) DNA synthesis rates in stably
transfected MDCK cells. [3H]dT incorporation in transfected
MDCK cells expressing TGF-a, CD9, or both, was measured as
in Fig. 6. The values, shown as bar graphs, represent the averages
of triplicates in two independent experiments with their SEM,
which are too small to be seen in this experiment. (B) Cell prolif-
eration, as measured by cell numbers, in stably transfected
MDCK cells, overexpressing TGF-a, CD9, or both. The SEM
values are too low to be visualized in the diagram. (C) Endoge-
nous expression of p21CIP1 in transfected MDCK cells, expressing
TGF-a, CD9, or both, as assessed by immunoprecipitation fol-
lowed by Western blot analysis.The Journal of Cell Biology, Volume 148, 2000 598
from the p21CIP1 promoter, as assessed using a p21CIP1 pro-
moter-luciferase reporter, transfected into the MDCK sta-
ble cells (data not shown). These results show that the high
level of EGFR activation, induced by coexpression of
transmembrane TGF-a and CD9, results in a high level of
p21CIP1 expression in MDCK cells. This increase in p21CIP1
expression, a CDK inhibitor that can induce growth arrest
when expressed beyond a certain threshold, may explain
why cells that coexpress TGF-a and CD9 proliferate at
a lower level than cells expressing TGF-a alone, even
though they have a higher level of EGFR activation.
Discussion
TGF-a and related growth factors are expressed as trans-
membrane proteins and bind to and activate the EGFR,
both as transmembrane proteins and as proteolytically re-
leased, soluble ligands (Derynck, 1992; Lee et al., 1995).
EGFR-induced signaling leads to the expression of vari-
ous genes and a proliferative response. The mechanisms of
signal propagation through these and other EGFR-acti-
vated pathways are well characterized (Schlessinger and
Ullrich, 1992; Moghal and Sternberg, 1999). In contrast,
little is known about how the ligands are presented to the
EGFR. Although transmembrane TGF-a activates the
EGFR (Brachmann et al., 1989; Wong et al., 1989), its pre-
sentation at the cell surface and its interaction with the
EGFR may be regulated by accessory proteins. We have
evaluated the ability of CD9, a membrane protein with
four predicted transmembrane segments, to associate with
transmembrane TGF-a.
CD9 can associate with the transmembrane forms of
HB-EGF and amphiregulin, and enhances their juxtacrine
proliferative effect (S. Higashiyama et al., 1995; Inui et al.,
1997). However, no interaction was observed between
CD9 and TGF-a, and no effect of CD9 on TGF-a–stimu-
lated DNA synthesis was seen in EGFR-expressing cells
(S. Higashiyama et al., 1995; Inui et al., 1997). These data,
together with peptide competition experiments, led to the
conclusion that CD9 interacts with the heparin-binding
domain of HB-EGF or amphiregulin, and not with trans-
membrane TGF-a, which lacks such a domain (Sakuma
et al., 1997). We now show that CD9 does associate with
transmembrane TGF-a, and that this interaction requires
the extracellular 50–amino acid core sequence of TGF-a.
Accordingly, CD9 does not interact with the aDE mutant
that lacks the TGF-a core sequence. In addition, trans-
membrane HB-EGF and TGF-a, which have sequence
similarity only in their EGF/TGF-a–like core sequence,
compete with each other for association with CD9. The in-
teraction of CD9 with TGF-a is most likely mediated
through the second and largest extracellular loop of
CD9, which has been implicated in the association with
HB-EGF.
CD9 and several other tetraspanins can associate with
several types of integrins (Berditchevski et al., 1996; Hem-
ler, 1998), and complexes of HB-EGF with CD9 and the
a3b1 integrin dimer have been observed (Nakamura et al.,
1995). Therefore, CD9 may play a role in cell surface pre-
sentation of transmembrane TGF-a and, through the for-
mation of oligomeric complexes with integrins, direct its
localization to sites of cell contact or cell adhesion. In this
way, CD9 could facilitate and increase the efficiency of the
TGF-a–induced stimulation of the EGFR, which has also
been localized at these sites. Tetraspanins, such as the
CD9-related CD151, CD63, and CD81, can also regulate
other types of intracellular signaling. CD63, CD81, and
CD151 recruit phosphatidylinositol 4-kinase toward the
integrin–tetraspanin complex (Berditchevski et al., 1997;
Yauch et al., 1998), and some protein kinase C isoforms
can be recruited into complexes of CD81 and CD151 with
integrins (Hemler, 1998). These observations raise the
possibility that the interaction of transmembrane TGF-a
with CD9 may mediate other signaling events, which await
further characterization.
The interaction of CD9 with transmembrane TGF-a
strongly decreased the serum- or PMA-induced ecto-
domain cleavage of TGF-a and consequent release of sol-
uble TGF-a. This observation may have considerable sig-
nificance. EGFR stimulation by e.g., TGF-a itself normally
induces the release of soluble TGF-a, thus, decreasing the
level of transmembrane TGF-a (Baselga et al., 1996; Fan
and Derynck, 1999). Whereas soluble EGF or TGF-a in-
duces internalization of the ligand–receptor complex and
consequent attenuation of the response, binding of trans-
membrane TGF-a to EGFR is unlikely to do so, and is ex-
pected to result in a high level, sustained activation of
EGFR. This would result in a much stronger EGFR re-
sponse, as in internalization-defective EGFR mutants
(Chen et al., 1989). Thus, expression of CD9 may inhibit
the autocrine feedback mechanism, which normally results
in TGF-a ectodomain cleavage and consequent attenua-
tion of EGFR signaling, and allow transmembrane TGF-a
to sustain signaling through the EGFR.
The much stronger stimulation of the EGFR induced by
coexpressing CD9 and TGF-a, when compared with TGF-a
expression alone, was evident from its increased tyrosine
phosphorylation. This was observed both in an autocrine
system, whereby TGF-a and CD9 were coexpressed in the
same MDCK cells as the EGFR, and in juxtacrine assays,
whereby the CD9/TGF-a–expressing cells were in contact
with the EGFR on adjacent cells. The increased EGFR ac-
tivation could be explained by inhibition of the TGF-a
ectodomain cleavage and consequent sustained signaling
by transmembrane TGF-a, combined with the higher lev-
els of uncleaved TGF-a at the cell surface. In addition,
CD9 coexpression may also increase the stability and half-
life of transmembrane TGF-a, and increased EGFR stim-
ulation may enhance the expression of transmembrane
TGF-a, as described previously (Coffey et al., 1987, Tang
et al., 1997). Whether the increase in transmembrane
TGF-a levels in the presence of CD9 fully accounts for the
increased EGFR activation is unclear, and additional ef-
fects of CD9 on the presentation of transmembrane
TGF-a to the EGFR (e.g., by increasing its affinity or con-
centrating it at the cell surface in clusters) may be envi-
sioned.
The effect of CD9 on the cell surface levels of the trans-
membrane growth factor may also explain why CD9 ex-
pression enhanced the juxtacrine mitogenic stimulation of
transmembrane HB-EGF (S. Higashiyama et al., 1995).
This would be consistent with the observed increase in
diphtheria toxin binding to cells that coexpress CD9 with
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in diphtheria toxin receptor binding sites on these cells
(Mitamura et al., 1992; Iwamoto et al., 1994). In contrast,
no major effect of CD9 on the cell surface levels of HB-
EGF, as assessed using an anti–HB-EGF antibody, was
detected (Iwamoto et al., 1994).
Consistent with the increased EGFR stimulation, CD9
enhanced the DNA synthesis in 32D cells, when compared
with the effect of transmembrane TGF-a alone. This
higher juxtacrine mitogenic response resembled the effect
of CD9 on the activity of HB-EGF in a similar assay (Hi-
gashiyama et al., 1995). In contrast, the autocrine mito-
genic activity of transmembrane TGF-a in MDCK cells
was decreased in the presence of CD9, even though the
level of EGFR activation (and TGF-a expression) was
much higher than in cells expressing TGF-a alone. EGFR-
induced growth inhibition has previously only been shown
in squamous carcinoma cells, such as A431 cells, with a
strongly amplified level of EGFR expression. In A431
cells, very low EGF levels induce a moderate proliferative
response, and the more commonly used EGF concentra-
tions induce growth inhibition (Kawamoto et al., 1984).
Thus, hyperstimulation of EGFR signaling because of ex-
tremely high EGFR levels can induce growth inhibition
(Kawamoto et al., 1984; MacLeod et al., 1986), presum-
ably from hyperstimulation of the Raf/MAP kinase signal-
ing cascade (Sewing et al., 1997; Woods et al., 1997) and
Stat signaling (Bromberg et al., 1998). Our data now show
that, in contrast to A431 cells, EGFR hyperstimulation
can lead to growth inhibition at the normal physiological
EGFR levels in epithelial cells, and that this can be
achieved by coexpressing CD9 and transmembrane TGF-a.
The autocrine growth inhibitory effect of CD9 in TGF-
a–expressing MDCK cells is in contrast with its stimula-
tory effect in juxtacrine assays using 32D cells. This differ-
ence in response does not correlate with higher EGFR
levels in MDCK versus 32D cells, as could have been in-
voked based on the findings in A431 cells. Instead, the en-
dogenous EGFR levels in MDCK cells are physiological
and lower than in EGFR-transfected 32D cells, and the
TGF-a levels in the transfected MDCK cells are lower
than in the transfected CHO cells, which were used in the
juxtacrine assays (data not shown). The growth inhibitory
effect of TGF-a/CD9 in an autocrine context versus the
stimulatory effect in juxtacrine assays may reflect a quali-
tative difference between these two modes of presentation
of TGF-a/CD9 to the EGFR. Alternatively or in addition,
this difference may also be due to cell type differences be-
tween the 32D cells of hematopoietic origin and the epi-
thelial MDCK cells.
The autocrine growth inhibitory effect of CD9 in TGF-
a–expressing MDCK cells was associated with a high ex-
pression level of p21CIP1. p21CIP1 binds to cdk4 and cdk2
complexes, and increased p21CIP1 expression inhibits cyclin
D– and cyclin E–dependent kinase activities and induces
growth inhibition (Morgan, 1995; el-Deiry, 1998). The
growth inhibitory effect of CD9 in TGF-a–expressing
MDCK cells is, therefore, likely to be a direct conse-
quence of the induction of p21Cip1. Accordingly, the
growth inhibitory effect of EGF on A431 cells with their
extremely high EGFR levels is also paralleled by an induc-
tion of p21CIP1 (Fan et al., 1995). Thus, p21CIP1 expression
and growth inhibition can be induced by EGFR hyper-
stimulation, either at highly amplified EGFR levels, such
as in A431 cells, or at normal physiological EGFR num-
bers, when CD9 is coexpressed with transmembrane TGF-a.
Induction of p21CIP1 as a result of EGFR stimulation may
also explain the decreased proliferation of cells expressing
transmembrane HB-EGF, when compared with cells ex-
pressing soluble HB-EGF (Miyoshi et al., 1997).
Finally, the association of CD9 with transmembrane
TGF-a and its effect on EGFR signaling may play a role in
the development of carcinoma tumors. When compared
with normal epithelial cells, carcinomas, especially squa-
mous carcinomas, frequently show increased TGF-a (Der-
ynck et al., 1987; Derynck, 1992; Lee et al., 1995) and
EGFR expression, and consequently high levels of EGFR
activation (Khazaie et al., 1993). Increased TGF-a levels
and autocrine EGFR activation are known to contribute
to carcinoma formation and proliferation in mice (Jhap-
pan et al., 1990; Matsui et al., 1990; Sandgren et al., 1990),
thus, suggesting that increased TGF-a and EGFR num-
bers may contribute to carcinoma development in humans.
The frequent expression of CD9 in carcinomas (Higash-
iyama et al., 1997; Adachi et al., 1998), combined with our
current findings, now raises the possibility that CD9 could
enhance autocrine, TGF-a signaling at normal EGFR lev-
els (i.e., without the need for increased EGFR levels) and,
in this way, regulate the behavior of carcinomas in vivo. A
few studies have correlated the expression of CD9 with
the clinical prognosis of carcinomas (Miyake et al., 1996;
Cajot et al., 1997; Huang et al., 1998). Although these cor-
relations have not been unambiguous, increased CD9 ex-
pression may correlate with a better prognosis of several
carcinoma types in humans. This could be due in part to
the decreased motility of cells with higher CD9 levels (Hi-
gashiyama et al., 1995; Miyake et al., 1996), and to physio-
logical consequences of the interaction of CD9 with inte-
grins. However, our results suggest that CD9 expression
may also affect tumor development through its ability to
regulate the TGF-a–induced activation of EGFR signaling
and, consequently, cell proliferation.
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